IP Library Patent Application 18908082
Patent Application
App. No. 18/908,082

ANTIGEN PREDICTIONS FOR INFECTIOUS DISEASE-DERIVED EPITOPES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/908,082
Abstract

Disclosed herein is a system and methods for determining the alleles, antigens, and infectious disease-based vaccine composition as determined on the basis of a patient's expressed HLA alleles. Additionally described herein are unique infectious disease-derived vaccines.

Claims (40)

1 . A method for identifying one or more infectious disease-derived antigens likely to be presented by cells of a subject, the method comprising:

obtaining peptide sequences of a plurality of infectious disease-derived antigens;

obtaining sequences of one or more MHC alleles of the subject;

inputting the peptide sequences of the plurality of infectious disease-derived antigens and the sequences of one or more MHC alleles of the subject into a multi-part presentation model to generate a set of numerical likelihoods that the plurality of infectious disease-derived antigens are presented by the one or more MHC alleles expressed on surfaces of cells of the subject,

wherein a first part of the multi-part presentation model comprises a pan-allele model portion that receives, as input, peptide sequences of one or more infectious disease-derived antigens and the sequences of one or more MHC alleles of the subject, or representations thereof, and

wherein a second part of the multi-part presentation model comprises a plurality of allele-specific models that each receives, as input, the peptide sequences of the plurality of infectious disease-derived antigens, or a representation thereof; and

selecting a subset of the plurality of infectious disease-derived antigens based on the set of numerical likelihoods to generate a set of selected antigens.

2 . The method of claim 1 , wherein the multi-part presentation model comprises a plurality of parameters generated using at least 1) mass spectrometry data and 2) binding affinity data determined from a plurality of samples.

3 . The method of claim 1 , wherein the multi-part presentation model comprises a plurality of parameters generated using a training dataset comprising:

training peptide sequences, and

for one or more of the training peptide sequences, a label derived from mass spectrometry data indicating whether the training peptide sequence was presented by one or more class I MHC alleles present in a plurality of samples.

4 . The method of claim 3 , wherein the training peptide sequences are identified through mass spectrometry on isolated peptides eluted from MHC alleles present in the plurality of samples.

5 . The method of claim 3 , wherein the multi-part presentation model comprises a plurality of parameters generated using a training dataset comprising:

for one or more of the training peptide sequences, a label derived from binding affinity data indicating whether the training peptide sequence was bound with one or more class I MHC alleles present in a plurality of samples.

6 - 8 . (canceled)

9 . The method of claim 1 , wherein the pan-allele model portion comprises a neural network.

10 . The method of claim 9 , wherein a first set of layers of the neural network of the pan-allele model portion performs a dimensional reduction of the sequences of one or more MHC alleles of the subject.

11 . The method of claim 9 , wherein a second set of layers of the neural network of the pan-allele model portion receives, as input, a representation of the peptide sequences of the plurality of infectious disease-derived antigens and a dimensionally reduced representation of the sequences of one or more MHC alleles of the subject.

12 . The method of claim 11 , wherein the representation of the peptide sequences of the plurality of infectious disease-derived antigens is generated by encoding the peptide sequences via a one-hot encoding scheme.

13 . The method of claim 11 , wherein the second set of layers of the neural network models interactions between the peptide sequences of the plurality of infectious disease-derived antigens and the sequences of one or more MHC alleles of the subject.

14 . The method of claim 1 , wherein one or more of the allele-specific models comprise a neural network.

15 . The method of claim 14 , wherein the neural network of the allele-specific network receives, as input, a representation of the peptide sequences of the plurality of infectious disease-derived antigens, and outputs per-allele presentation likelihoods for an allele.

16 . The method of claim 15 , wherein the representation of the peptide sequences of the plurality of infectious disease-derived antigens is generated by encoding the peptide sequences via a one-hot encoding scheme.

17 - 21 . (canceled)

22 . The method of claim 1 , wherein the cells of the subject comprise cells infected with one of a pathogen, virus, bacteria, fungus, or a parasite.

23 . The method of claim 1 , wherein infectious disease-derived antigens originate from one of a pathogen, virus, bacteria, fungus, or a parasite.

24 . The method of claim 1 , wherein infectious disease-derived antigens originate from an infectious disease organism selected from the group consisting of: severe acute respiratory syndrome-related coronavirus (SARS), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Ebola, HIV, Hepatitis B virus (HBV), influenza, Hepatitis C virus (HCV), Human papillomavirus (HPV), Cytomegalovirus (CMV), Chikungunya virus, Respiratory syncytial virus (RSV), Dengue virus, a orthymyxoviridae family virus, tuberculosis, pancorona, herpes simplex virus infection (HSV), flu, metapneumovirus (MPV), and Parainfluenza Viruses (PIVs).

25 . A method of treating a subject for an infectious disease comprising performing claim 1 , and further comprising obtaining a vaccine comprising the set of selected antigens, and administering the vaccine to the subject.

26 - 27 . (canceled)

28 . A method of manufacturing a vaccine, comprising performing claim 1 , and further comprising producing or having produced a vaccine comprising the set of selected antigens.

29 . A vaccine comprising a set of selected antigens selected by performing the method claim 1 .

30 - 33 . (canceled)

34 . A non-transitory computer readable medium comprising instructions that, when executed by a processor, cause the processor to:

obtain peptide sequences of a plurality of infectious disease-derived antigens;

obtain sequences of one or more MHC alleles of the subject;

input the peptide sequences of the plurality of infectious disease-derived antigens and the sequences of one or more MHC alleles of the subject into a multi-part presentation model to generate a set of numerical likelihoods that the plurality of infectious disease-derived antigens are presented by the one or more MHC alleles expressed on surfaces of cells of the subject,

wherein a first part of the multi-part presentation model comprises a pan-allele model portion that receives, as input, peptide sequences of one or more infectious disease-derived antigens and the sequences of one or more MHC alleles of the subject, or representations thereof, and

wherein a second part of the multi-part presentation model comprises a plurality of allele-specific models that each receives, as input, the peptide sequences of the plurality of infectious disease-derived antigens, or a representation thereof; and

select a subset of the plurality of infectious disease-derived antigens based on the set of numerical likelihoods to generate a set of selected antigens.

35 - 57 . (canceled)

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ERRONEOUS REFERENCE TO APPLICATION NUMBERS 10847252, 10847253 AND 11183286 TO INSTEAD REFLECT THE PATENT NUMBERS LISTED IN THE RECORDED ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED ON REEL 70760 FRAME 165. ASSIGNOR(S) HEREBY CONFIRMS THE THE ASSIGNMENT. Recorded Apr 25, 2025
From: GRITSTONE BIO, INC.
To: SEATTLE PROJECT CORP.
Reel/Frame 071079/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2025
From: GRITSTONE BIO, INC.
To: SEATTLE PROJECT CORP.
Reel/Frame 070760/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2025
From: KLEIN, JOSHUA; CAO, MINH DUC
To: GRITSTONE BIO, INC.
Reel/Frame 070546/0271 →